Palatin TechnologiesPTN
Recorded

Palatin Technologies 2027 Q1 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ1 2027Duration39 minParticipants7

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, everyone. Welcome to Palatin's first quarter fiscal year 2027 operating results conference call. As a reminder, this conference call is being recorded. Before we begin our remarks, I would like to remind you that statements made by Palatin are not historical facts and may be forward-looking statements. These statements are based on assumptions that may or may not prove accurate and that actual results may differ materially from those anticipated due to the variety of risks and uncertainties discussed in the company's most recent filings with the Securities and Exchange Commission. Please consider such risks and uncertainties carefully in evaluating these forward-looking statements by Palatin's prospects. Now, I would like to turn the call over to your host, Dr. Carl Spana, President and Chief Executive Officer of Palatin.

Carl SpanaCEO and President

Please go ahead. Good morning, and welcome to Palatin's fiscal first quarter 2027 call.

Carl SpanaCEO and President

I am Dr. Carl Spana, CEO and President of Palatin. With me on the call today is Steve Wills, Palatin's Chief Financial Officer and Chief Operating Officer.

Steve WillsCFO and COO

Steve. Thank you, Carl, and good morning, everyone.

Steve WillsCFO and COO

I will review our financial results for the fiscal 2027 first quarter ended September 30, 2026, and discuss our operating priorities and provide some perspective on our financial strategy as we move toward important clinical development milestones. During the quarter, we continued to focus our resources on advancing our next-generation MC4R programs, particularly the IND-enabling activities for our lead lipidated peptide and the development of our oral small molecule candidates. We believe these investments are positioning Palatin for an important period of clinical development beginning in calendar year 2027. Regarding fiscal first quarter financial results, for the three months ended September 30, 2026, Palatin recognized approximately $362,000 in collaboration and license revenue compared with approximately $8.8 million for the comparable prior year period. Current quarter revenue was attributable to research and development services performed under our collaboration with Boehringer Ingelheim.

Steve WillsCFO and COO

The prior year period included substantial upfront milestone payments associated with that agreement, which accounts for the year-over-year difference. Turning to expenses, research and development were approximately $3.4 million compared with approximately $2.5 million in the comparable prior year period. Importantly, spending directly related to our MC4R obesity development programs increased to approximately $2.1 million compared with approximately $1 million in the prior year period. This increase reflects our continued advancement of IND-enabling studies and related development activities for our long-acting peptide program, as well as lead candidate optimization activities for our oral small molecule program. We believe these expenditures represent important investments in advancing our development candidates toward clinical evaluation. General and administrative expenses were approximately $2.1 million compared with approximately $1.7 million in the comparable prior year period. The increase was primarily attributable to a higher stock-based compensation expense and professional fees.

Steve WillsCFO and COO

For the fiscal first quarter, we reported a net loss of approximately $5.1 million, or $1.29 per basic and diluted common share. Regarding Palatin's cash position and financial strategy, net cash used in operating activities was approximately $3.7 million during the quarter compared with approximately $1.6 million in the prior year period. As of September 30, 2026, we had approximately $3.7 million in cash and cash equivalents. We recognize that advancing our development programs through the next stages of clinical development will require additional capital. We are evaluating financing alternatives, including public and private equity transactions, while continuing to pursue strategic collaborations and other opportunities to support our programs. Our financing strategy is directed toward obtaining the capital necessary to execute our development plans and achieve the milestones that we believe can create substantial value for Palatin and its shareholders.

Steve WillsCFO and COO

We have successfully accessed the capital markets and executed strategic transactions throughout Palatin's history, and we remain focused on pursuing the financial resources required to advance our programs. At the same time, we continue to carefully manage operating expenditures and prioritize investment in our highest value development opportunities. Regarding strategic partnerships and operating priorities, an important component of our strategy is utilizing our broader melanocortin portfolio to create additional opportunities for value through licensing and collaboration agreements. Our partnership with Boehringer Ingelheim and our licensing arrangement with Altanispac Labs provide opportunities for future economic participation while allowing us to concentrate our internal resources on our MC4R obesity programs. We also continue to evaluate strategic opportunities for our other development assets in the MC1R landscape. Looking ahead, our operating priorities remain clear.

Steve WillsCFO and COO

First, advance our lead lipidated MC4R peptide candidate through the necessary IND-enabling and manufacturing activities toward initiation of a phase I clinical study in the first half of calendar year 2027. Second, progress our oral small molecule MC4R program toward candidate selection, IND-enabling development, and planned clinical initiation in the second half of calendar year 2027. Third, continue expanding the opportunities within our MC4R portfolio, including our non-lipidated peptide series and oral peptide approach. Fourth, secure the financial and strategic resources necessary to support these objectives. In closing, Palatin is entering an important period in its development. Our strategic direction is clearly established, our next-generation MC4R programs are advancing, and our research and development investments are increasingly concentrated on programs with the potential for significant clinical and commercial differentiation. We believe Palatin has the scientific expertise, proprietary compounds, and development capabilities to compete effectively in this emerging market.

Steve WillsCFO and COO

We remain confident in the potential of our programs and committed to advancing them through the next important stages of development. With that, I'll turn the call back to Carl.

Carl SpanaCEO and President

Carl? Thank you, Steve. Today, I want to focus on the significant opportunity we see for Palatin with our next-generation of melanocortin four receptor-targeted therapies, the progress we are making across our development programs, and the important milestones ahead.

Carl SpanaCEO and President

The treatment landscape for rare neuroendocrine obesity disorders continues to evolve rapidly. Importantly, melanocortin four receptor, or MC4 receptor agonism, has now been clinically and commercially validated as a therapeutic approach for patients with certain rare obesity disorders driven by dysfunctions in the melanocortin pathway. This validation is important. It establishes that activating the MC4 receptor can deliver meaningful clinical benefits in diseases that have historically been extremely difficult to treat. This provides substantial opportunities for novel, differentiated MC4 therapeutics, which is where Palatin is focused.

Carl SpanaCEO and President

Our objective is to develop next-generation MC4 agonists with the potential to deliver robust efficacy, substantially improved tolerability, minimal or no hyperpigmentation, and dosing profiles that are practical for patients who may require treatment throughout their lives. We are applying our extensive knowledge of melanocortin receptor pharmacology, peptide engineering, and drug development to create therapies designed to address the limitations of existing and emerging products. An important differentiating characteristic of our development programs is receptor selectivity. The melanocortin four receptor is the receptor principally associated with the regulation of appetite, food intake, and energy balance, while the melanocortin one receptor is involved in skin pigmentation. Activation of melanocortin one receptor can cause skin darkening or hyperpigmentation, which has emerged as a challenge in the development of MC4-based agonist therapeutics. For patients with rare obesity disorders who may require lifelong treatment, minimizing this effect is important.

Carl SpanaCEO and President

Our strategy is to selectively activate the melanocortin four receptor while avoiding MC1 activity. Tested compounds from our two next-generation peptide series have demonstrated potent melanocortin four receptor agonist activity without acting as agonists at the melanocortin one receptor. We believe this is a meaningful achievement and supports our objective of substantially reducing and potentially eliminating all MC1-mediated hyperpigmentation. Our goal is to develop MC4 therapeutics with clinically meaningful efficacy without requiring patients to accept unnecessary adverse effects associated with off-target receptor activation. We believe this is going to be an important differentiating factor. Turning to our lead program, we continue to make progress advancing our lipidated long-acting melanocortin four receptor-selective peptide towards clinical development. Our lead candidate is part of our PL2000 peptide series. In preclinical studies using diet-induced obese mice, this candidate demonstrated significant reductions in food intake and body weight following once-weekly subcutaneous administration.

Carl SpanaCEO and President

Importantly, pharmacokinetic findings in larger animals supports the potential for once-weekly or even less frequent dosing in humans. These attributes are central to our development strategy. For patients with chronic lifelong conditions such as hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, a therapy that combines robust efficacy with convenient dosing and improved tolerability could represent or does represent important advancements in the field. Our lipidated peptide approach is designed to extend drug exposure and pharmacological activity, potentially enabling sustained therapeutic benefits with fewer injections. We are currently advancing the IND-enabling preclinical and manufacturing activities necessary to support our first in-human study. We are targeting initiation of a phase I single and multiple ascending dose study in the first half of calendar 2027, with initial clinical data target to occur in the second half of the year. This represents an important upcoming milestone for Palatin.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day